International Journal of Drug Delivery Technology
Volume 14, Issue 1

Formulation and Evaluation of Microspheres Drug Delivery for Multiple Sclerosis Disease Condition

Kiran K Jadhav*, Gangadharappa H V

Department of Pharmaceutics, JSS College of Pharmacy, JSS Academic of Higher Education & Research, Sri Shivarathreeshwara Nagara, Mysuru, Karnataka, India. 

Received: 09th July, 2023; Revised: 21st January, 2024; Accepted: 04th February, 2024; Available Online: 25th March, 2024

ABSTRACT

Multiple sclerosis (MS) is chronic inflammatory disease that affecting the central nervous system (CNS) which leads to the degeneration of oligodendrocytes, neurons, and myelin over time. Being the foremost reason of neurological disability multiple sclerosis has affected about 2.5 million humans around the world. MS is mainly seen in early adulthood and adults in their middle age. Disease modifying agents are being used in treatment of relapsing multiple sclerosis. Medications that reduce the severity of the disease are frequently utilized as standard therapies. The immune system is the primary focus of modern MS treatments. However, researchers are putting more effort into designing novel CNS-focused treatments. Therefore, under the current scenario, an alternative route for drug delivery is required, one that provides a speedy onset of action and then maintains the drug release over an extended period. The desired prolong-acting intramuscular injecting stable fingolimod HCl microspheres to treat MS were formulated using solvent evaporation technique. Further, based on the number of factors to be optimized, formulation was prepared using solvent evaporation. Additionally, the formulated fingolimod microspheres were characterized for the size distribution of particle, particle surface morphology, and lyophilization of formulated microspheres. Post lyophilization, the formulated microspheres evaluation was done for efficiency of entrapment, drug release in-vitro, and stability parameters. Furthermore, in-vivo studies were performed on suitable animal models for the optimized formulation.

Keywords: Formulation, Multiple sclerosis, Microsphere, Lyophilization, Particle size, Drug release, Drug content. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.1.13

How to cite this article: Jadhav KK, Gangadharappa HV. Formulation and Evaluation of Microspheres Drug Delivery for Multiple Sclerosis Disease Condition. International Journal of Drug Delivery Technology. 2024;14(1):79-93.

REFERENCES

  1. McGinley MP, Goldschmidt CH, Rae-Grant Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA - Journal of the American Medical Association. 2021 23;325(8):765–79.
  2. Meghrajani VR, Marathe M, Sharma R, Potdukhe A, Wanjari MB, Taksande A Comprehensive Analysis of Mental Health Problems in India and the Role of Mental Asylums. Cureus. 2023 Jul 27;15(7): e42559.
  3. Cree BAC, Arnold DL, Chataway J, Chitnis T, Fox RJ, Pozo Ramajo A, et Secondary Progressive Multiple Sclerosis: New Insights. Neurology. 2021; 97(8):378.
  4. Huang WJ, Chen WW, Zhang Multiple sclerosis: Pathology, diagnosis and treatments. Exp Ther Med. 2017; 13(6):3163.
  5. Weinberg BD, Kuruva M, Shim H, Mullins ME. Clinical applications of magnetic resonance spectroscopy (MRS) in of brain tumors: from diagnosis to treatment. Radiol Clin North Am. 2021, 59(3):349.
  6. Gallo PM, Gallucci S. The Dendritic Cell Response to Classic, Emerging, and Homeostatic Danger Signals. Implications for Autoimmunity. Front Immunol. 2013; [2]; 324.
  7. Apostolopoulos V, Matsoukas Advances in Multiple Sclerosis Research-Series I. Brain Sci. 2020; 10(11):1–7.
  8. Thöne J, Ellrichmann G. Oral available agents in the treatment of relapsing remitting multiple sclerosis an overview of merits and culprits. Drug Healthc Patient Saf. 2013 ;5(1):37–47.
  9. Wei W, Ma D, Li L, Zhang L. Progress in the Application of Drugs for the Treatment of Multiple Front Pharmacol. 2021 Jul 13; 12:1793.
  10. Da Silva PV, de Queiroz Long term multiple sclerosis drug delivery using dendritic polyglycerol flower-like microspheres 2019; 22 [2];31(2):188–206.
  11. Kabanov A V., Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci. 2007; [2];32(8–9):1054.
  12. Bourganis V, Kammona O, Alexopoulos A, Kiparissides C. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. European Journal of Pharmaceutics and Biopharmaceutics. 2018; 1; 128:337–62.
  13. Vinogradov S V. Colloidal microgels in drug delivery Curr Pharm Des. 2006; 12(36):4703.
  14. Lima AF, Amado IR, Pires LR. Poly (d, l-lactide-co-glycolide) (PLGA) Nanoparticles Loaded with Proteolipid Protein (PLP)— Exploring a New Administration Route. Polymers (Basel). 2020;12(12):1–10.
  15. Robertson D, Moreo Disease-Modifying Therapies in Multiple Sclerosis: Overview and Treatment Considerations. Federal Practitioner. 2016; [2];33(6):28.
  16. Weinstock-Guttman B, Medin J, Khan N, Korn JR, Lathi E, Silversteen J, et al. Assessing “No Evidence of Disease Activity” Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study. CNS Drugs. 2018; 1;32(1):75–84.
  17. Von Wyl V, Benkert P, Moser A, Lorscheider J, Décard B, Hänni P, et al. Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer 2021;27(3):439–48.
  18. Jin X, Xu X, Zhang X, Yin Determination of the PCM melting temperature range using DSC. Thermochim Acta. 2014; 10;595: 17–21.
  19. Gill P, Moghadam TT, Ranjbar B. Differential Scanning Calorimetry Techniques: Applications in Biology and Nanoscience. J Biomol Tech. 2023; 21(4):167.
  20. Chen W, Palazzo A, Hennink WE, Kok Effect of particle size on drug loading and release kinetics of gefitinib-loaded PLGA microspheres. Mol Pharm. 2017;14(2):459–67.
  21. Devhare LD and Gokhale Antioxidant and antiulcer property of different solvent extracts of cassia tora linn. Research journal of pharmacy and technology. 2022, 15(3): 1109-1113
  22. Lale S V, Goyal M, Bansal AK. Development of lyophilization cycle and effect of excipients on the stability of catalase during lyophilization. Int J Pharm Investig. 2011;1(4):214.
  23. Effat Souri Mohammad Zargarpoor, Siavash Mottaghi, Reza Ahmadkhaniha, and Abbas Kebriaeezadeh A Stability- Indicating HPLC Method for the Determination of Fingolimod in Pharmaceutical Dosage Forms Sci 2015; 83(1): 85–93.
  24. Kalyana Chakravarthy V, Gowri Sankar LC Determination of fingolimod in bulk and its pharmaceutical formulation. Imperial J. Medicinal & Organic Chemistry 2011; 1(1): 10-17.
  25. Kotta Kranthi Kumar, Pankaj Kumar Sharma and L. Srinivas Development of agglomerated crystals of Irbesartan by spherical crystallization technique for enhancing the micrometric and solubility property published in International Journal of Pharmaceutical Sciences and Nanotechnology,2016; 9(2);3193-3207.
  26. Kotta Kranthi Kumar, Pankaj Kumar Sharma and L. Srinivas Development of agglomerated crystals of Olmesartan Medoxomil by spherical crystallization technique for enhancing the micrometric and solubility property publishes in World journal of pharmacy,2016; Vol.5(3);646-675.
  27. Kotta Kranthi Kumar Design and evaluation of the multi particulate system of extended-release indomethacin capsules USP, Research journal of pharmaceutical, biological and chemical sciences, 2010; vol.1(4); 74-82.
  28. Tamakuwala M, Stagni G. Fingolimod Hydrochloride Gel for Dermatological Applications: Optimization of Formulation Strength and Effect of Colloidal Oatmeal (Aveeno®) as Penetration AAPS PharmSciTech, 2016; 17(4):907–14.
  29. Guidance for Industry Q1A (R2) Stability Testing of New Drug Substances and Products S. Department of Health and Human Services Food and Drug Administration Revision 2 2003; 1-13.
  30. Schwarz C, Mehnert W. Freeze-drying of drug-free and drug- loaded solid lipid nanoparticles (SLN). International Journal of Pharmaceutics. 1997;157(2):171-9.
  31. John M Kovarik , Stefan Hartmann, Michael Bartlett, Gilles- Jacques Riviere, Daniel Neddermann, Yibin Wang, Andreas Port, Robert L Schmouder Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects Biopharm Drug Dispos. 2007; 28(2):97-104.
  32. Zhiliang Xie Min Chen Swagata Goswami, Rajes Mani, Dasheng Wang, Samuel Kulp, Chris C. Coss, Larry J. Schaaf, Fengyu Cui, John C. Byrd, Ryan N. Jennings, Karsten K. Schober, Carrie Freed, Stephanie Lewis, Raphael Malbrue, Natarajan Muthusamy, Chad Bennett, William C. Kisseberth, and Mitch Phelps Pharmacokinetics and Tolerability of the Novel Non- immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats AAPS J. 2020; 16; 22(4): 92.
  33. Fracasso, ; Passoni, A.; Brambilla, L.; Mantegazza, R.; Rossi, S.; Gobbi, M.; Lucchetti, J. A Validated HPLC-MS/MS Method for Quantification of Fingolimod and Fingolimod-Phosphate in Human Plasma: Application to Patients with Relapsing– Remitting Multiple Sclerosis. Appl. Sci. 2022; 12, 6102.
  34. Hao-Liang Xu, Dale A Pelligrino, Chanannait Paisansathan, and Fernando D Testail Protective role of fingolimod (FTY720) in rats subjected to subarachnoid hemorrhage J Neuroinflammation. 2015; 12: 16.
  35. Gnana RPM, Devhare LD, Dharmamoorthy G, Khairnar MV, Prasidha R. Synthesis, Characterisation, Molecular Docking Studies and Biological Evaluation of Novel Benzothiazole Derivatives as EGFR Inhibitors for Anti-breast Cancer Agents. International Journal of Pharmaceutical Quality Assurance. 2023;14(3):475-480.
  36. Sonule M, Devhare LD, Babu MN, Gunjal SD, Varalaxmi S. Microemulgel-based Hydrogel of Diclofenac Sodium using Lipidium sativum as a Gelling Agent. International Journal of Drug Delivery Technology. 2023;13(4):1235-1239.